U10 Ful Member Application Affiliated with SWOG

描述（由申请人提供）：UT M。D.安德森癌症中心（MDACC）于2002年11月加入西南肿瘤学小组（SWOG），成为正式成员。这是我们的第一个U10会员申请。在过去的3年中，在成为SWOG正式成员之前，MDACC平均每年为SWOG治疗研究提供51项应计项目。我们的SWOG计划将整合MDACC综合多学科资源的许多要素，包括16个专业护理中心，其中大多数MDACC患者作为门诊患者接受多学科，多模态团队方法的治疗。MDACC拥有895名癌症研究人员，其中包括536名临床教师。2001年，医疗发展和社区咨询中心照顾了62 600名癌症病人，其中16 144人是新诊断的，3 500人参加了治疗方案。协调SWOG研究的结构包括主要研究者、联合主要研究者、CRA负责人、SWOG项目指导委员会和每个疾病中心项目的负责人（医学肿瘤学家、放射治疗师、外科医生）。每一位MDACC-SWOG项目的疾病现场负责人都是MDACC癌症医学部执行理事会的部门主席，由Waun Ki Hong博士领导，他热情支持MDACC内部的SWOG治疗/累积活动。MDACC在过去6年中对SWOG的重大行政贡献包括癌症控制研究委员会主席和SWOG执行委员会/科学咨询委员会成员（李普曼博士）;胃肠道委员会主席 (Dr. Abbruzzese）;脑委员会联合主席（Sawaya博士）;肺发育治疗委员会副主席（Herbst博士）;睾丸小组委员会主席（Logothetis博士）;肉瘤（特殊人群）委员会副主席（Bleyer博士）。至少有21名MDACC教师是SWOG的正式成员，并定期积极为几个SWOG委员会做出贡献（例如，胃肠、脑、肺、H & N和肉瘤委员会）。EI-Naggar博士将领导SWOG H&N肿瘤生物学和相关科学小组委员会。P. Pisters博士是SWOG肉瘤标本委员会的顾问。至少有11名MDACC教师在17个SWOG协调协议（包括3个开发中）中担任研究协调员，并共同撰写了18篇SWOG论文（自2000年以来）。MDACC将利用其历史优势，在SWOG环境中开发创新的I期和II期研究。III期试验非常复杂，任何一个机构都难以单独进行，MDACC期待着领导一些并加入其他SWOG努力，以测试III期标准治疗试验中的新方法。

DESCRIPTION (provided by applicant): The UT M. D. Anderson Cancer Center (MDACC) joined the Southwest Oncology Group (SWOG) as a full member in November 2002. This is our first U10 member application. During the past 3 years and entirely prior to becoming a full SWOG member, MDACC averaged 51 accruals to SWOG therapy studies per year. Our SWOG Program will integrate many elements of MDACCs comprehensive multidisciplinary resources, including 16 specialized Care Centers, where most MDACC patients are treated as outpatients in a multidisciplinary, multimodality team approach. MDACC has 895 cancer research faculty, including 536 clinical faculty. In 2001, MDACC cared for 62,600 cancer patients, of whom 16,144 were newly diagnosed and 3,500 were enrolled in therapeutic protocols. The structure for coordinating SWOG studies includes the Principal Investigator, Co-Principal Investigator, Head CRA, SWOG Program Steering Committee, and leaders of each disease-site program (medical oncologists, radiotherapists, surgeons). Every MDACC-SWOG Program disease-site leader is a MDACC department chair sitting on the Executive Council of the Division of Cancer Medicine headed by Dr. Waun Ki Hong, who enthusiastically supports SWOG therapy/accrual activities within MDACC. Substantial MDACC administrative contributions to SWOG in the past 6 years include Chair, Cancer Control Research Committee and member, SWOG Executive Committee/Scientific Advisory Board (Dr. Lippman); Chair, Gastrointestinal Committee (Dr. Abbruzzese); Co-Chair, Brain Committee (Dr. Sawaya); Vice Chair, Lung Developmental Therapeutics Committee (Dr. Herbst); Chair, Testis Subcommittee (Dr. Logothetis); and Vice Chair, Sarcoma (Special Populations) Committee (Dr. Bleyer). At least 21 MDACC faculty are official members of SWOG and contribute actively to several SWOG committees on a regular basis (e.g., the Gastrointestinal, Brain, Lung, H & N, and Sarcoma committees). Dr. EI-Naggar will head the SWOG H&N Tumor Biology and Correlative Science Subcommittee. Dr. P. Pisters is a consultant for the SWOG Sarcoma Specimen Board. At least 11 MDACC faculty provided scientific leadership as Study Coordinators in 17 SWOG-coordinated protocols (including 3 in development) and co-authored 18 SWOG papers (since 2000). MDACC will apply its historical strengths in developing innovative Phase I, II studies within the SWOG setting. Phase III trials are highly complex and difficult for any single institution to conduct alone, and MDACC looks forward to leading some and joining other SWOG efforts to test novel approaches in Phase Ill, standard-of-care-altering trials.